NCT00022919

Brief Summary

This study will examine prostate tumor tissue cultures to try to identify genetic abnormalities that contribute to the cause or progression of the disease. Patients with prostate cancer enrolled in the National Cancer Institute protocol 97-C-0147 (Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Disease) may be eligible for this study. Specimens for tissue culture for this study will be obtained from tumors surgically removed from patients participating in NCI protocol 97-C-0146. The findings of this study may lead to better methods of predicting the course of disease in individual patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2001

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2001

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

August 16, 2001

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 17, 2001

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2004

Completed
Last Updated

March 4, 2008

Status Verified

August 1, 2004

First QC Date

August 16, 2001

Last Update Submit

March 3, 2008

Conditions

Prostate Cancer

Keywords

MicrodissectionChromosomeKaryotypeTumorMalignancyProstate AdenocarcinomaProstate Intraepithelial NeoplasiaProstate CancerProstate

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Only patients who have met pathologic criteria for prostate intraepithelial neoplasia or higher (determined by pathologists included in the NCI protocol) will be included for entry into this protocol.

You may not qualify if:

  • No prisoners, decisionally impaired, healthy volunteers, or lab personnel will be included in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Human Genome Research Institute (NHGRI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40. doi: 10.1073/pnas.95.4.1735.

    PMID: 9465086BACKGROUND

  • Nupponen NN, Isola J, Visakorpi T. Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer. 2000 Jun;28(2):203-10.

    PMID: 10825005BACKGROUND

  • Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech. 2000 Dec 1;51(5):456-63. doi: 10.1002/1097-0029(20001201)51:53.0.CO;2-H.

    PMID: 11074616BACKGROUND

MeSH Terms

Conditions

Prostatic NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

August 16, 2001

First Posted

August 17, 2001

Study Start

August 1, 2001

Study Completion

August 1, 2004

Last Updated

March 4, 2008

Record last verified: 2004-08

Locations

US(1)